Elorac, Inc., a rapidly growing specialty pharmaceutical company focused
on the treatment of dermatological disorders, announced today that Scott
B. Phillips, M.D., has joined the Company as Senior Vice President,
Dr. Phillips will be primarily responsible for the continued clinical
development of Elorac's robust pipeline of medical dermatology product
candidates. He will manage both ongoing clinical projects as well as
direct the expansion of clinical research into new development projects.
A board-certified dermatologist, Dr. Phillips will also provide clinical
support to Elorac's sales and marketing efforts as well as
Previously Director of Drug Discovery at GenDerm Corporation and Senior
Vice President, Scientific Affairs at Winston Pharmaceuticals, Dr.
Phillips has 23 years of experience in the pharmaceutical industry. In
addition, hehas been Chief of the Clinical Investigations Unit at
Harvard Medical School and Clinical Assistant Professor of Dermatology
and Medicine at the University of Chicago Pritzker School of Medicine.
He received a B.A. in biology from Cornell University and an M.D. from
John Kallal, Ph.D., Elorac's former Vice President, Clinical and
Regulatory Affairs, announced his retirement as a full-time employee,
but he will remain actively involved in supporting Elorac's clinical
programs as a consultant.
"We are excited to add Dr. Phillips to our team at Elorac," said Jeffrey
Bernstein, Ph.D., President and Chief Executive Officer. "Scott has an
excellent background and a proven track record in navigating new
products through the drug regulatory approval process. As a company
dedicated to innovations in medical dermatology, we are pleased to add
additional depth to our executive team."
About Elorac, Inc.
Elorac, Inc. is a privately owned, specialty pharmaceutical company
engaged in the development and commercialization of novel products for
dermatology, allergy and oncology. The Company markets dermatological
products in the United States through its own dedicated sales force.
Elorac has a robust pipeline of products in development, including
naloxone lotion for treatment of pruritus accompanying cutaneous T-cell
lymphoma, a product that has received orphan drug and fast-track
designations from the U.S. Food and Drug Administration, and cidoxepin,
the most potent histamine antagonist ever discovered, for chronic
urticaria. According to Inc. magazine's 2013 list of
fastest-growing private U.S. companies, Elorac ranked 23rd among
health-care companies and No. 1 among pharmaceutical companies.
[ Back To NFVZone's Homepage ]